KOSPI large cap
Hanmi Pharm.
A leading Korean pharma strong in new-drug development and incrementally modified drugs. KOSPI large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
128940.KS Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21-34.1%'22+6.5%'23+28.5%'24-24.3%'25+98.4%YTD-19.3%
Money in ▸·
Hanmi Pharm.~₩1.5T
▸ Money out·
Financials & Segments
- Total revenue · ~₩1.5T (FY2024)
- Segments · Prescription drugs · Overseas and licensing · Beijing Hanmi (China)
Revenue from
No refined links yet.
Pays to
No refined links yet.